Points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 - EULAR | Cliniscan
Cliniscan
Solutions
Tarifs
Ressources
Se connecter
Essayer gratuitement
Cliniscan
Retour aux recommandations
EULAR
2021
·
Europe
·
Rheumatology
Points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19
Document
Analyser ce document
